• Net sales for the period amounted to SEK 15.5 M (13.1) • Profit after tax totaled SEK 5.3 M (4.5) • Earnings per share amounted to SEK 0.47 (0.40) • Operating profit amounted to SEK 7.3 M (6.2) • Cash flow from operating activities amounted to SEK 12.2 M (6.7) Johan Löf, President and CEO of RaySearch Laboratories AB, comments on the first three months of the year as follows: “RaySearch continued to show growth. Sales for the first three months of the year amounted to SEK 15.5 M, an increase of 18 percent, compared with the same period in the preceding year. Operating profit also increased by 18 percent and amounted to SEK 7.3 M for the first three months of the year. The number of licenses sold remained at a relatively stable level. Sales of OM-Optimizer were distinctly lower than expected. Nucletron took extensive operational measures to improve sales, but these measures are expected to impact on sales first in the second half of the year. Support revenues doubled, and their share of revenues amounted to about 20 percent. In that the installed base is constantly growing, the importance of support revenues is increasing. RaySearch has a strong financial position with favorable cash flow and very high liquidity. During 2005, a letter of intent was signed with Philips to enter into a long-term development and licensing agreement in adaptive radiation treatment. Negotiations have taken longer than anticipated. RaySearch signed the final agreement on March 17, 2006, and the expectation was that Philips also would sign the agreement relatively quickly. Formal procedural issues within Philips, however, had the result that the agreement is not yet final. We wish to emphasize that RaySearch does not see any reason whatsoever to believe anything other than that the agreement will be signed by both parties in the near future. Within the framework of the new license agreement signed between RaySearch and Scanditronix-Wellhöfer in February, the companies will create efficient and competitive systems for automated quality assurance of IMRT. Scanditronix-Wellhöfer is very advanced in detector technology and has a large installed base in a segment to which RaySearch did not have access previously. It is very positive that we can now begin collaboration with the leading player in the market for dosimetric measurement equipment and the agreement constitutes a natural and exciting expansion of our product portfolio. The goal is to develop three completely new products, of which the first two can be expected to reach the market in 2007. All clinics offering IMRT are potential customers.” Stockholm, May 9, 2006 RaySearch Laboratories AB Johan Löf, CEO For further information, contact: Johan Löf, CEO RaySearch Laboratories AB Telephone: +46 (0)8-545 061 30 johan.lof@raysearchlabs.com
Press releases
